Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135

Authors: Keyserling, Harry L; Pollard, Andrew J; DeTora, Lisa M; Gilmet, Gregory P

Source: Expert Review of Vaccines, Volume 5, Number 4, August 2006 , pp. 445-459(15)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Invasive disease due to Neisseria meningitidis continues to cause debility and death worldwide in otherwise healthy individuals. Disease epidemiology varies globally, but most cases are due to serogroups A, B, C, W-135 or Y. MenactraTM (MCV-4), a quadrivalent, meningococcal diphtheria-conjugate vaccine against serogroups A, C, Y, and W-135, was licensed in the USA for individuals 11-55 years of age. Published results of clinical trials demonstrated robust immune responses that correlate with indicators of protection. MCV-4-induced antibody persist for up to 3 years after administration and anamnestic responses to revaccination. The vaccine was well tolerated; the most common reactions were transient, mild injection-site reactions and headache. MCV-4 should provide significant clinical benefits in the future.

Keywords: conjugate vaccine; MCV-4; Menactra; meningococcal disease; vaccine

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14760584.5.4.445

Publication date: 2006-08-01

More about this publication?

Expert Review of Vaccines provides expert reviews on the clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines in bioterrorism.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites